Clinical decision support
The companies will create a value-based care program to support cardiology patients and providers at health systems and CINs.
The company will use the funds to expand its workforce, including its sales team, in order to broaden its biopharma partnerships.
The funding comes a year after the company announced an expanded relationship with OpenAI to develop a chatbot for healthcare providers built on GPT-4.
It has also received Australia's regulatory approval for its AI solution.
Also, Kakao Healthcare is extending access to its AI to a public diabetes screening programme in South Korea.
It has shown 96% accuracy in predicting fall risks in over 70,000 outpatients in Japan.
Rad AI's genAI tools will be offered through Bayer's vendor-neutral Calantic Digital Solution marketplace, which provides AI-enabled clinical and operational applications.
Also, insurtech company Huize from China is expanding to Southeast Asia.
LifeSemantics plans to commercialise its mobile app-based AI screening solution by yearend.
Interestingly, young physicians see more risk to it than their senior counterparts.